Zydus Lifesciences Limited has informed the Exchange regarding a press release dated December 09, 2025, titled "Zydus and Formycon enter into an Exclusive Partnership for the Licensing and Supply of Biosimilar to Keytruda® (Pembrolizumab), in US and Canada".
Press Release Dec 09 2025
Filed with NSE · · 3 pages · English
Summary by 6ix AI
This partnership marks Zydus' entry into the North American biosimilar market, aiming to enhance access to affordable oncology care. The press release emphasizes the collaboration's potential to drive growth and improve patient access to immunotherapy treatments.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Zydus and Formycon enter into an Exclusive Partnership for the Licensing and Supply of Biosimilar to Keytruda® (Pembrolizumab), in US and Canada
- Press Release Dec 04 2025
- Press Release Nov 27 2025
- Press Release Nov 26 2025
- Zydus and RK Pharma enter into an exclusive licensing and commercialization agreement for a novel 505(b)(2) product of supportive oncology treatment for the USA market
Later from Zydus Lifesciences
- Press Release Dec 10 2025
- Press Release Dec 15 2025
- Zydus Lifesciences Limited Press Release Dec 19 2025
- Zydus Partners with Bioeq for U.S. Commercialisation rights for NUFYMCO®, an Interchangeable Biosimilar to Lucentis®
- Press Release Dec 23 2025
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences